RLAY Q3 2025 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$748,000

Operating Income

-$80M

Net Income

-$74M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$670M

Total Liabilities

$62M

Stockholders' Equity

$608M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$748,000	$0	—
Operating Income	-$80M	-$96M	+16.6%
Net Income	-$74M	-$88M	+15.8%